

16/4 IFW

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))


Docket No.
19059

In Re Application Of: Jose Repolles Moliner, et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/544,237	August 2, 2005	Unassigned	23389	Unassigned	Unassigned

Title:

DISULFIDE, SULFIDE, SULFOXIDE, AND SULFONE DERIVATIVES OF CYCLIC SUGARS AND USES THEREOF



Address to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
19059

In Re Application of: Jose Repolles Moliner, et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/544,237	August 2, 2005	Unassigned	23389	Unassigned	Unassigned

Title:

DISULFIDE, SULFIDE, SULFOXIDE, AND SULFONE DERIVATIVES OF CYCLIC SUGARS AND USES THEREOF

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____) on _____ (Date) _____ Signature _____
Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on February 15, 2006 (Date) _____ Signature of Person Mailing Correspondence _____
Frank S. DiGiglio
Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Dated: February 15, 2006

Frank S. DiGiglio
Registration No. 31,346
Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
516-742-4343

CC:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Jose Repolles Moliner, et al. **Examiner:** Unassigned
Serial No: 10/544,237 **Art Unit:** Unassigned
Filed: August 2, 2005 **Docket:** 19059
For: DISULFIDE, SULFIDE, SULFOXIDE, **Dated:** February 15, 2006
AND SULFONE DERIVATIVES OF
CYCLIC SUGARS AND USES THEREOF

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT


In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. United States Patent No. 3,886,186, dated May 27, 1975 to Dvornich et al., which corresponds to French Patent Publication No. 2 134 698, published December 8, 1972;
2. Spanish Patent Publication No. 2 142 773, published April 16, 2000, which corresponds to United States Patent No. 6,858,632 B2, dated February 22, 2005 to Moliner et al. and PCT International Publication No. WO 00/20420, published April 13, 2000;
3. United States Patent No. 4,371,703, dated February 1, 1983 to Stoss;

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner of Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Dated: February 15, 2006



Frank S. DiGiglio

4. Excerpt from the Orange Book, Record Search Query on "020225" (2005);
5. Excerpt from the Orange Book, Record Search Query on "020215" (2005);
6. "Isosorbide Mononitrate", Information from Answers.com (2005);
7. Part of a document referred to as "Myocardial Heart Attack",
<http://www.mailxmail.com/curso/vida/infartomiocardio/capitulo6.htm> (2005);
and
8. "Monoket® Tablets", *Schwarz Pharma*, PC3734A (1999).

Applicants are submitting a copy of the above-cited references. Please note that the French counterpart to reference no. 1 and the PCT publication to reference no. 2 were previously submitted in an Information Disclosure Statement dated September 27, 2005. In accordance with the waiver of 37 C.F.R. § 1.98 (a)(2)(i) in effect as of June 30, 2003, applicants are not required to submit a copy of the above-cited U.S. Patent references.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.


Respectfully submitted,



Frank S. DiGiglio
Registration No.: 31,346

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343

FSD:dg

Form PTO-1449
(REV. 7-80) U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**LIST OF PRIOR ART
CITED BY APPLICANT***(Use several sheets if necessary)*

Atty. Docket No. (Optional)

19059

Application Number

10/544,237

Applicant(s)

Jose Repolles Moliner, et al.

Filing Date

August 2, 2005

Group Art Unit

Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA	3,886,186	5/27/75	Dvouch et al.			
	AB	6,858,632 B2	2/22/05	Moliner et al.			
	AC	4,371,703	2/1/83	Stoss			

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		2 142 773	4/16/00	Spain				✓

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

		Excerpt from the Orange Book, Record Search Query on "020225" (2005)
		Excerpt from the Orange Book, Record Search Query on "020215" (2005)
		"Isosorbide Mononitrate", Information from Answers.com (2005)
		Part of a document referred to as "Myocardial Heart Attack", http://www.mailxmail.com/cursio/vida/infartomiocardio/capitulo6.htm (2005)
		"Monoket® Tablets", Schwarz Pharma, PC3734A (1999)

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.